Pub Date : 2023-11-22DOI: 10.5354/2735-7996.2014.72806
Mario Matamala C., Miguel Guzmán N., Javiera Aguirre E.
Febrile seizures are the most common seizure disorder in the pediatric population and represent a frequent cause of consultation in emergency departments, confirming its importance. We present an updated and practical review regarding this pathology, along with an operative definition that supports the application of a flowchart that integrates concepts and procedures that can be easily applied at any location nationwide. This review is designed to provide an analytic framework regarding pediatric febrile seizures, as well as present a guideline based on our experience in the emergency department by summarizing the main benzodiazepines in actual use that have been proved to be both safe and effective in treating this disorder, such as lorazepam and midazolam
{"title":"Convulsión febril","authors":"Mario Matamala C., Miguel Guzmán N., Javiera Aguirre E.","doi":"10.5354/2735-7996.2014.72806","DOIUrl":"https://doi.org/10.5354/2735-7996.2014.72806","url":null,"abstract":"Febrile seizures are the most common seizure disorder in the pediatric population and represent a frequent cause of consultation in emergency departments, confirming its importance. We present an updated and practical review regarding this pathology, along with an operative definition that supports the application of a flowchart that integrates concepts and procedures that can be easily applied at any location nationwide. This review is designed to provide an analytic framework regarding pediatric febrile seizures, as well as present a guideline based on our experience in the emergency department by summarizing the main benzodiazepines in actual use that have been proved to be both safe and effective in treating this disorder, such as lorazepam and midazolam","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139248361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.5354/2735-7996.2023.71414
Pedro Lobos Z., Jamileth More C., Bárbara Bruna J., Antonello Penna S.
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the progressive deterioration of cognitive functions such as memory, language, executive function, and visuospatial function, starting from the late ages of life (> 65 years). The etiology of AD is multifactorial involving the interaction of genetic, environmental, and systemic factors. Histopathologically characterized by the progressive accumulation of peptide Aβ and TAU protein. Markers of damage that begin to accumulate decades before symptoms can be detected. However, during the early stages of the disease, systemic inflammation and cortical/hippocampal hyperactivity have been revealed present in patients. In the following review, we present a perspective on how neuroinflammatory processes and pathological cortical hyperexcitability contribute to the onset and development of the early stages of AD. We present a current summary of the basic and clinical evidence that allows us to understand the complexity and heterogeneity of this pathology. Finally, we briefly collect and analyze the main therapeutic strategies that have been studied to reduce the phenotype of neuronal hyperactivity directly or indirectly.
{"title":"Nuevas estrategias farmacológicas en la enfermedad de Alzheimer: la hiperactividad y la neuroinflamación como nuevos blancos potenciales","authors":"Pedro Lobos Z., Jamileth More C., Bárbara Bruna J., Antonello Penna S.","doi":"10.5354/2735-7996.2023.71414","DOIUrl":"https://doi.org/10.5354/2735-7996.2023.71414","url":null,"abstract":"Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the progressive deterioration of cognitive functions such as memory, language, executive function, and visuospatial function, starting from the late ages of life (> 65 years). The etiology of AD is multifactorial involving the interaction of genetic, environmental, and systemic factors. Histopathologically characterized by the progressive accumulation of peptide Aβ and TAU protein. Markers of damage that begin to accumulate decades before symptoms can be detected. However, during the early stages of the disease, systemic inflammation and cortical/hippocampal hyperactivity have been revealed present in patients. In the following review, we present a perspective on how neuroinflammatory processes and pathological cortical hyperexcitability contribute to the onset and development of the early stages of AD. We present a current summary of the basic and clinical evidence that allows us to understand the complexity and heterogeneity of this pathology. Finally, we briefly collect and analyze the main therapeutic strategies that have been studied to reduce the phenotype of neuronal hyperactivity directly or indirectly.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134478947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.5354/2735-7996.2023.71406
María Gabriela Caballero Q., Guillermo Conte L.
Ovarian vein thrombosis is a rare condition that is usually due to prothrombotic states. The clinical presentation is nonspecific, commonly with abdominal pain. Anticoagulation is fundamental to prevent complications and reduce morbidity and mortality. Enoxaparin and warfarin have traditionally been the anticoagulants of choice. Direct-acting anticoagulants are an alternative under study. This publication presents a case of a 60-year-old patient without predisposing factors for ovarian thrombosis, with low back pain, where the diagnosis was only achieved with Computed Tomography. Anticoagulation with rivaroxaban was started for a period of 3 months, obtaining resolution of symptoms and thrombosis.
{"title":"Un extraño caso de trombosis venosa","authors":"María Gabriela Caballero Q., Guillermo Conte L.","doi":"10.5354/2735-7996.2023.71406","DOIUrl":"https://doi.org/10.5354/2735-7996.2023.71406","url":null,"abstract":"Ovarian vein thrombosis is a rare condition that is usually due to prothrombotic states. The clinical presentation is nonspecific, commonly with abdominal pain. Anticoagulation is fundamental to prevent complications and reduce morbidity and mortality. Enoxaparin and warfarin have traditionally been the anticoagulants of choice. Direct-acting anticoagulants are an alternative under study. This publication presents a case of a 60-year-old patient without predisposing factors for ovarian thrombosis, with low back pain, where the diagnosis was only achieved with Computed Tomography. Anticoagulation with rivaroxaban was started for a period of 3 months, obtaining resolution of symptoms and thrombosis.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133624800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.5354/2735-7996.2023.71407
T. González A., Sally Costa C., Nicolás Espinoza C., C. Erazo C.
Introduction: Secondary rhinoplasty, or reintervention, is a surgery on a previously operated nose, which represents a greater surgical challenge compared to primary rhinoplasty. The ideal is the use of autologous cartilage graft since it meets biocompatibility characteristics and resembles an ideal graft. The costal cartilage is a good alternative since it has characteristics similar to septal cartilage, with the advantage of offering a larger amount of material to work with and it does not deform over time. Clinical case: male, 31 years old, admitted due to a hit to the face with a blunt object. It evidenced complex facial fracture, with Le Fort I components on the right and Le Fort III components on the left, as well as a left naso-orbital-ethmoid fracture. It performs reduction and intermaxillary fixation. It performs nasal reconstruction with a double nasal cartilage graft and bone graft for the back, and septal cartilage graft to construct the columella stem. It plans secondary rhinoplasty with a seventh rib graft correct the saddle nose defect. Outpatient follow-up at 14 and 30 days with favorable cosmetic results. Discussion: This procedure generally gives good results with a low complication rate. In the latest systematic reviews with an average follow-up of 14.4 months (6-96 months) they concluded that in the donor area the most frequent complication was the development of scars in the surgical site with 2.08% (0. 31-4.83%) and pneumothorax was close to 0% (0-0.46%). In the recipient area, the most frequent were graft retraction with 3.05% (1.35-5.19%) and 1.45% (0.34-3.06%) of infection of the recipient area. Conclusion: With the presentation of this clinical case, you can observed that the use of costal cartilage in secondary rhinoplasty is an achievable option, with good results in the short and medium term, in addition to having a low rate of complications, but a team of experienced plastic surgery must perform it. Fecha recepción: noviembre 2022 | Fecha aceptación: febrero
简介:二次鼻成形术，或称再介入手术，是对以前手术过的鼻子进行的手术，与初次鼻成形术相比，它代表了更大的手术挑战。理想的是使用自体软骨移植，因为它符合生物相容性特征，类似于理想的移植物。肋软骨是一个很好的选择，因为它具有与间隔软骨相似的特征，具有提供大量材料的优势，并且不会随着时间的推移而变形。临床病例:男性，31岁，因脸部被钝器击中而入院。其表现为复杂的面部骨折，右侧为Le Fort I型骨折，左侧为Le Fort III型骨折，以及左侧鼻眶筛骨折。它用于复位和上颌间固定。采用双鼻软骨移植和背部骨移植，鼻中隔软骨移植重建鼻小柱干。它计划用第七根肋骨进行二次鼻整形，以纠正鞍鼻缺陷。门诊随访14天和30天，美容效果良好。讨论:该手术通常效果良好，并发症发生率低。在最新的系统回顾中，平均随访14.4个月(6-96个月)，他们得出结论，在供体区，最常见的并发症是手术部位瘢痕的形成，占2.08%(0.08%)。31-4.83%)，气胸接近0%(0-0.46%)。受区感染以移植物牵伸最多，分别占3.05%(1.35 ~ 5.19%)和1.45%(0.34 ~ 3.06%)。结论:通过本临床病例的介绍，可以看出肋软骨二期鼻成形术是一种可实现的选择，中短期效果良好，并发症发生率低，但必须由经验丰富的整形外科医生进行。Fecha recepción: noviem2022 | Fecha aceptación: febrero
{"title":"Reconstrucción nasal secundaria con injerto costal: caso clínico y revisión de la literatura","authors":"T. González A., Sally Costa C., Nicolás Espinoza C., C. Erazo C.","doi":"10.5354/2735-7996.2023.71407","DOIUrl":"https://doi.org/10.5354/2735-7996.2023.71407","url":null,"abstract":"Introduction: Secondary rhinoplasty, or reintervention, is a surgery on a previously operated nose, which represents a greater surgical challenge compared to primary rhinoplasty. The ideal is the use of autologous cartilage graft since it meets biocompatibility characteristics and resembles an ideal graft. The costal cartilage is a good alternative since it has characteristics similar to septal cartilage, with the advantage of offering a larger amount of material to work with and it does not deform over time. Clinical case: male, 31 years old, admitted due to a hit to the face with a blunt object. It evidenced complex facial fracture, with Le Fort I components on the right and Le Fort III components on the left, as well as a left naso-orbital-ethmoid fracture. It performs reduction and intermaxillary fixation. It performs nasal reconstruction with a double nasal cartilage graft and bone graft for the back, and septal cartilage graft to construct the columella stem. It plans secondary rhinoplasty with a seventh rib graft correct the saddle nose defect. Outpatient follow-up at 14 and 30 days with favorable cosmetic results. Discussion: This procedure generally gives good results with a low complication rate. In the latest systematic reviews with an average follow-up of 14.4 months (6-96 months) they concluded that in the donor area the most frequent complication was the development of scars in the surgical site with 2.08% (0. 31-4.83%) and pneumothorax was close to 0% (0-0.46%). In the recipient area, the most frequent were graft retraction with 3.05% (1.35-5.19%) and 1.45% (0.34-3.06%) of infection of the recipient area. Conclusion: With the presentation of this clinical case, you can observed that the use of costal cartilage in secondary rhinoplasty is an achievable option, with good results in the short and medium term, in addition to having a low rate of complications, but a team of experienced plastic surgery must perform it. \u0000Fecha recepción: noviembre 2022 | Fecha aceptación: febrero","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132016533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.5354/2735-7996.2023.71243
P. Délano R.
No abstract available
没有摘要
{"title":"Investigación, innovación y desarrollo tecnológico en el Hospital Clínico Universidad de Chile","authors":"P. Délano R.","doi":"10.5354/2735-7996.2023.71243","DOIUrl":"https://doi.org/10.5354/2735-7996.2023.71243","url":null,"abstract":"No abstract available","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134448200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-12DOI: 10.5354/2735-7996.2017.70647
Revista Hospital Clínico Universidad de Chile
Desde hace unos años, el Hospital Clínico Universidad de Chile a través de su Dirección de Calidad ha esta- blecido un espacio de desarrollo y enriquecimiento institucional de sus prácticas y está enfocado en contribuir a la formación de una cultura de calidad y seguridad de los pacientes que permita posicionar y alinear la calidad en todos los niveles del quehacer de su Institución. Es por esto que desde hace unos años organiza las Jornadas de Calidad HCUCH en las cuales se presentan trabajos realizados localmente que tuvieron como objetivo la obtención de mejores resultados en la atención de los pacientes. A continuación compartimos los trabajos presentados en su versión 2017.
{"title":"Abstracts Jornadas de Calidad 2017","authors":"Revista Hospital Clínico Universidad de Chile","doi":"10.5354/2735-7996.2017.70647","DOIUrl":"https://doi.org/10.5354/2735-7996.2017.70647","url":null,"abstract":"Desde hace unos años, el Hospital Clínico Universidad de Chile a través de su Dirección de Calidad ha esta- \u0000blecido un espacio de desarrollo y enriquecimiento institucional de sus prácticas y está enfocado en contribuir \u0000a la formación de una cultura de calidad y seguridad de los pacientes que permita posicionar y alinear la \u0000calidad en todos los niveles del quehacer de su Institución. Es por esto que desde hace unos años organiza las \u0000Jornadas de Calidad HCUCH en las cuales se presentan trabajos realizados localmente que tuvieron como \u0000objetivo la obtención de mejores resultados en la atención de los pacientes. A continuación compartimos los \u0000trabajos presentados en su versión 2017.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128189708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-09DOI: 10.5354/2735-7996.2017.70606
Álvaro Sepúlveda-Martínez, E. Segovia R, Mauro Parra-Cordero
1. Conocer la morbilidad materna asociada a la hipertensión durante el embarazo. 2. Conocer la morbilidad fetal y perinatal asociada a la hipertensión durante el embarazo. 3. Aplicar las estrategias de prevención de preeclampsia en pacientes hipertensas. 4. Conocer la terapia farmacológica validada para el manejo de la hipertensión durante el embarazo. 5. Determinar cifras tensionales para inicio de terapia farmacológica antihipertensiva oral. 6. Determinar cifras tensionales para inicio de terapia antihipertensiva endovenosa. 7. Aplicar metas tensionales para el manejo farmacológico antihipertensivo. 8. Establecer la edad gestacional de interrupción de pacientes portadoras de hipertensión arterial crónica. 9. Aplicar terapias antihipertensivas recomendadas durante la lactancia.
{"title":"Serie guías clínicas: manejo de la hipertensión crónica en el embarazo","authors":"Álvaro Sepúlveda-Martínez, E. Segovia R, Mauro Parra-Cordero","doi":"10.5354/2735-7996.2017.70606","DOIUrl":"https://doi.org/10.5354/2735-7996.2017.70606","url":null,"abstract":"1. Conocer la morbilidad materna asociada a la hipertensión durante el embarazo. \u00002. Conocer la morbilidad fetal y perinatal asociada a la hipertensión durante el embarazo. \u00003. Aplicar las estrategias de prevención de preeclampsia en pacientes hipertensas. \u00004. Conocer la terapia farmacológica validada para el manejo de la hipertensión durante el \u0000embarazo. \u00005. Determinar cifras tensionales para inicio de terapia farmacológica antihipertensiva oral. \u00006. Determinar cifras tensionales para inicio de terapia antihipertensiva endovenosa. \u00007. Aplicar metas tensionales para el manejo farmacológico antihipertensivo. \u00008. Establecer la edad gestacional de interrupción de pacientes portadoras de hipertensión \u0000arterial crónica. \u00009. Aplicar terapias antihipertensivas recomendadas durante la lactancia.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114077235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18DOI: 10.5354/2735-7996.2018.70354
Natalia Covarrubias R., A. Madrid S., René Rojas B., M. Gompertz G.
Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults.
{"title":"Calprotectina fecal: utilidad en el diagnóstico diferencial de enfermedad inflamatoria intestinal y síndrome intestino irritable en adultos","authors":"Natalia Covarrubias R., A. Madrid S., René Rojas B., M. Gompertz G.","doi":"10.5354/2735-7996.2018.70354","DOIUrl":"https://doi.org/10.5354/2735-7996.2018.70354","url":null,"abstract":"Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117238586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18DOI: 10.5354/2735-7996.2018.70356
Revista Hospital Clínico Universidad de Chile
Desde hace unos añ os, el Hospital Clínico Universidad de Chile a través de su Dirección de Calidad ha esta- blecido un espacio de desarrollo y enriquecimiento institucional de sus prácticas, enfocado en contribuir a la formación de una cultura de calidad y seguridad de los pacientes que permita alinear éstas en todos los niveles del quehacer de su Institución. Es por esto que se ha establecido como una de las estrategias de difusión, ampliación y profundización de los temas de seguridad y calidad institucional, la realización de las Jornadas de Calidad HCUCH. En ellas se presentan trabajos que corresponden a iniciativas locales que tuvieron como objetivo la obtención de mejores resultados en la atención de los pacientes. A continuación compartimos una selección de los trabajos presenta- dos en su versión 2018.
{"title":"Abstracts Jornadas Calidad 2018","authors":"Revista Hospital Clínico Universidad de Chile","doi":"10.5354/2735-7996.2018.70356","DOIUrl":"https://doi.org/10.5354/2735-7996.2018.70356","url":null,"abstract":"Desde hace unos añ os, el Hospital Clínico Universidad de Chile a través de su Dirección de Calidad ha esta- \u0000blecido un espacio de desarrollo y enriquecimiento institucional de sus prácticas, enfocado en contribuir a la \u0000formación de una cultura de calidad y seguridad de los pacientes que permita alinear éstas en todos los niveles \u0000del quehacer de su Institución. \u0000Es por esto que se ha establecido como una de las estrategias de difusión, ampliación y profundización de los \u0000temas de seguridad y calidad institucional, la realización de las Jornadas de Calidad HCUCH. En ellas se \u0000presentan trabajos que corresponden a iniciativas locales que tuvieron como objetivo la obtención de mejores \u0000resultados en la atención de los pacientes. A continuación compartimos una selección de los trabajos presenta- \u0000dos en su versión 2018.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129480467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18DOI: 10.5354/2735-7996.2023.70355
Revista Hospital Clínico Universidad de Chile
No abstract available
没有摘要
{"title":"Resúmenes IV Jornadas de Investigación 2022: \"Salud e ingeniería: soluciones innovadoras en HCUCH\"","authors":"Revista Hospital Clínico Universidad de Chile","doi":"10.5354/2735-7996.2023.70355","DOIUrl":"https://doi.org/10.5354/2735-7996.2023.70355","url":null,"abstract":"No abstract available","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122189981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：